GPT and Hepatic steatosis: A 24-week glargine treatment in newly diagnosed diabetes mellitus type 2 patients with NAFLD diagnoses resulted in reductions in liver steatosis, TG, free fatty acid (FFA), WC, ALT and GGT and improved glucose management control, measured by the improvement of the HbA1c level.